drugset
drugset / Trial / NCT00065429

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

NCT00065429 ↗

Phase 1/2 Completed 64 enrolled ImmunoGen, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.

Timeline

Start
2003-04
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorvotuzumab Mertansine Monoclonal antibody 5 mg/m2 Intravenous
Subject Lorvotuzumab Mertansine Monoclonal antibody 10 mg/m2 Intravenous
Subject Lorvotuzumab Mertansine Monoclonal antibody 20 mg/m2 Intravenous
Subject Lorvotuzumab Mertansine Monoclonal antibody 40 mg/m2 Intravenous
Subject Lorvotuzumab Mertansine Monoclonal antibody 60 mg/m2 Intravenous
Subject Lorvotuzumab Mertansine Monoclonal antibody 67.5 mg/m2 Intravenous
Subject Lorvotuzumab Mertansine Monoclonal antibody 75 mg/m2 Intravenous

Indications

small cell lung carcinoma